Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis

Open access

Abstract

Tirzepatide is a novel, once weekly, dual GIP/GLP-1 receptor agonist and is under development for the treatment of type 2 diabetes (T2D) and obesity. Its association with cardiovascular outcomes requires evaluation. This pre-specified cardiovascular meta-analysis included all seven randomized controlled trials with a duration of at least 26 weeks from the tirzepatide T2D clinical development program, SURPASS. The pre-specified primary objective of this meta-analysis was the comparison of the time to first occurrence of confirmed four-component major adverse cardiovascular events (MACE-4; cardiovascular death, myocardial infarction, stroke and hospitalized unstable angina) between pooled tirzepatide groups and control groups. A stratified Cox proportional hazards model, with treatment as a fixed effect and trial-level cardiovascular risk as the stratification factor, was used for the estimation of hazard ratios (HRs) and confidence intervals (CIs) comparing tirzepatide to control. Data from 4,887 participants treated with tirzepatide and 2,328 control participants were analyzed. Overall, 142 participants, 109 from the trial with high cardiovascular risk and 33 from the six trials with lower cardiovascular risk, had at least one MACE-4 event. The HRs comparing tirzepatide versus controls were 0.80 (95% CI, 0.57–1.11) for MACE-4; 0.90 (95% CI, 0.50–1.61) for cardiovascular death; and 0.80 (95% CI, 0.51–1.25) for all-cause death. No evidence of effect modifications was observed for any subgroups, although the evidence was stronger for participants with high cardiovascular risk. Tirzepatide did not increase the risk of major cardiovascular events in participants with T2D versus controls.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-022-01707-4

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Primary and secondary cardiovascular outcomes confirmed by central-blinded adjudication. Data are point estimates of HR (illustrated by the diamond symbol) and range of two-sided 95% CI of the HR. aStrata size adjusted estimate. Strata are defined as trial-level cardiovascular risk (SURPASS-4 forms one stratum, and all other trials form one stratum) bDeath due to cardiovascular cause includes adjudication-confirmed death due to cardiovascular or undetermined cause. cMACE-3 includes death due to cardiovascular or undetermined cause, MI and stroke. Note: P values were based on the Wald chi-square test. n, number of participants in the specified category.
Fig. 1 Primary and secondary cardiovascular outcomes confirmed by central-blinded adjudication. Data are point estimates of HR (illustrated by the diamond symbol) and range of two-sided 95% CI of the HR. aStrata size adjusted estimate. Strata are defined as trial-level cardiovascular risk (SURPASS-4 forms one stratum, and all other trials form one stratum) bDeath due to cardiovascular cause includes adjudication-confirmed death due to cardiovascular or undetermined cause. cMACE-3 includes death due to cardiovascular or undetermined cause, MI and stroke. Note: P values were based on the Wald chi-square test. n, number of participants in the specified category.CC BY · PubMed Central
Fig. 2 Adjusted Kaplan–Meier plot of pooled tirzepatide versus pooled comparator effect on time to first occurrence of adjudication-confirmed MACE-4 (primary outcome). Gray bars represent the planned follow-up period for trials GPGB (30 weeks); SURPASS-1, SURPASS-2 and SURPASS-5 (44 weeks); SURPASS-3 and SURPASS J-mono (56 weeks); and SURPASS-4 (56–108 weeks). Note: P values were based on the Wald chi-square test.
Fig. 2 Adjusted Kaplan–Meier plot of pooled tirzepatide versus pooled comparator effect on time to first occurrence of adjudication-confirmed MACE-4 (primary outcome). Gray bars represent the planned follow-up period for trials GPGB (30 weeks); SURPASS-1, SURPASS-2 and SURPASS-5 (44 weeks); SURPASS-3 and SURPASS J-mono (56 weeks); and SURPASS-4 (56–108 weeks). Note: P values were based on the Wald chi-square test.CC BY · PubMed Central
Fig. 3 Time to first occurrence of adjudication-confirmed MACE-4 by trial groupings. Adjusted Kaplan–Meier estimates. a, Time to first occurrence of composite MACE-4, pooled tirzepatide versus insulin glargine, insulin degludec and placebo combined and mITT population. Gray bars represent the planned follow-up period for trials GPGB (30 weeks); SURPASS-1 and SURPASS-5 (44 weeks); and SURPASS-3 (56 weeks). b, Time to first occurrence of adjudicated-confirmed MACE-4, pooled tirzepatide versus insulin glargine, SURPASS-4 only and mITT population. Gray bar represents the planned follow-up period for SURPASS-4 (56–108 weeks). Note: P values were based on the Wald chi-square test.
Fig. 3 Time to first occurrence of adjudication-confirmed MACE-4 by trial groupings. Adjusted Kaplan–Meier estimates. a, Time to first occurrence of composite MACE-4, pooled tirzepatide versus insulin glargine, insulin degludec and placebo combined and mITT population. Gray bars represent the planned follow-up period for trials GPGB (30 weeks); SURPASS-1 and SURPASS-5 (44 weeks); and SURPASS-3 (56 weeks). b, Time to first occurrence of adjudicated-confirmed MACE-4, pooled tirzepatide versus insulin glargine, SURPASS-4 only and mITT population. Gray bar represents the planned follow-up period for SURPASS-4 (56–108 weeks). Note: P values were based on the Wald chi-square test.CC BY · PubMed Central
Fig. 4 Other adjudication-confirmed cardiovascular outcomes. Data are point estimates of HR (illustrated by the diamond symbol) and range of two-sided 95% CI of the HR. aStrata size adjusted estimate. Strata are defined as trial-level cardiovascular risk (SURPASS-4 forms one stratum, and all other trials form one stratum). bMACE-6 includes MACE-3 and all other adjudication-confirmed cardiovascular outcomes: HUA, HHF and coronary revascularization. n, number of participants in the specified category.
Fig. 4 Other adjudication-confirmed cardiovascular outcomes. Data are point estimates of HR (illustrated by the diamond symbol) and range of two-sided 95% CI of the HR. aStrata size adjusted estimate. Strata are defined as trial-level cardiovascular risk (SURPASS-4 forms one stratum, and all other trials form one stratum). bMACE-6 includes MACE-3 and all other adjudication-confirmed cardiovascular outcomes: HUA, HHF and coronary revascularization. n, number of participants in the specified category.CC BY · PubMed Central
Fig. 5 Subgroup analyses of the effects of tirzepatide on the adjudication-confirmed composite MACE-4. Data are point estimates of HR (illustrated by the diamond symbol) and range of two-sided 95% CI of the HR. aStrata size adjusted estimate. Strata are defined as trial-level cardiovascular risk (SURPASS-4 forms one stratum, and all other trials form one stratum). bDerived from a Cox proportional hazards model with treatment (pooled tirzepatide versus pooled comparator), the subgroup variable and the treatment-by-subgroup interaction term as fixed effects, stratified by study-level cardiovascular risk (SURPASS-4 forms one stratum, and all other trials form one stratum) for subgroups other than stratum. Pre-specified subgroup analyses were by sex, age and baseline HbA1c; the rest of the analyses were post hoc. P value is from the Wald chi-square test. N, number of participants in the subgroup in population; n, number of participants in the specified category.
Fig. 5 Subgroup analyses of the effects of tirzepatide on the adjudication-confirmed composite MACE-4. Data are point estimates of HR (illustrated by the diamond symbol) and range of two-sided 95% CI of the HR. aStrata size adjusted estimate. Strata are defined as trial-level cardiovascular risk (SURPASS-4 forms one stratum, and all other trials form one stratum). bDerived from a Cox proportional hazards model with treatment (pooled tirzepatide versus pooled comparator), the subgroup variable and the treatment-by-subgroup interaction term as fixed effects, stratified by study-level cardiovascular risk (SURPASS-4 forms one stratum, and all other trials form one stratum) for subgroups other than stratum. Pre-specified subgroup analyses were by sex, age and baseline HbA1c; the rest of the analyses were post hoc. P value is from the Wald chi-square test. N, number of participants in the subgroup in population; n, number of participants in the specified category.CC BY · PubMed Central
Extended Data Fig. 1 Time-to-event analyses of composite adjudication-confirmed MACE-4. Data are point estimate of HR (illustrated by the diamond symbol) and range of 2-sided 95% CI of the HR. aStrata size adjusted estimate. Strata are defined as trial-level cardiovascular risk (SURPASS-4 forms one stratum, and all other trials form one stratum). Abbreviations: CI = confidence interval; HR = hazard ratio; iDeg = insulin degludec; iGlar = insulin glargine; MACE = major adverse cardiovascular events; n = number of participants in the specified category; PBO = placebo; TZP = tirzepatide.
Extended Data Fig. 1 Time-to-event analyses of composite adjudication-confirmed MACE-4. Data are point estimate of HR (illustrated by the diamond symbol) and range of 2-sided 95% CI of the HR. aStrata size adjusted estimate. Strata are defined as trial-level cardiovascular risk (SURPASS-4 forms one stratum, and all other trials form one stratum). Abbreviations: CI = confidence interval; HR = hazard ratio; iDeg = insulin degludec; iGlar = insulin glargine; MACE = major adverse cardiovascular events; n = number of participants in the specified category; PBO = placebo; TZP = tirzepatide.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Cited by

See all 346

Metadata

Authors
Sattar, N., McGuire, D. K., Pavo, I., Weerakkody, G. J., Nishiyama, H., Wiese, R. J., & Zoungas, S.
Affiliations
  • University of Glasgow (GB)
  • Parkland Health & Hospital System (US)
  • Eli Lilly (United States) (US)
  • Monash University (AU)
Corresponding author
  • Sattar, Naveed
  • Zoungas, Sophia
Venue
Nature Medicine
Published
2022-02-24
Volume
28
Issue
3
Pages
591-598
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4213427170
Cited by
346
References
39
Citations by year
2026: 43 · 2025: 72 · 2024: 93 · 2023: 94 · 2022: 44
FWCI
10.78
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
Funders
British Heart Foundation (RE/18/6/34217)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
tirzepatide, major adverse cardiovascular events, cardiovascular safety, type 2 diabetes, obesity, GIP/GLP-1 receptor agonist, cardiovascular mortality, myocardial infarction, stroke, unstable angina, SURPASS trials, effect modification
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Humans, Hypoglycemic Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. https://app.cochat.ai/papers/10.1038/s41591-022-01707-4
The paper
Sattar, N., McGuire, D. K., Pavo, I., Weerakkody, G. J., Nishiyama, H., Wiese, R. J., & Zoungas, S. (2022). Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nature Medicine. https://doi.org/10.1038/s41591-022-01707-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.